Retroscreen Virology Group plc - Board changes

12 Jun 2014

Retroscreen Virology Group plc (AIM: RVG), the pioneer of hVIVO human challenge models of disease, is pleased to announce further strategic changes to its Board of Directors ("Board") as part of the Company's ambitious growth strategy.  Jaime Ellertson has been appointed as Non-Executive Chairman, with immediate effect, succeeding David Norwood, who will continue to play a pivotal role on the Board as a Non-Executive Director.

Jaime Ellertson (55) has a strong track record of leading fast growing, data and service driven companies through phases of rapid expansion, both in the private and public arena.  Jaime is currently Chairman and Chief Executive Officer of Everbridge Inc., a provider of multidimensional critical communications solutions to leading Health Care, Corporate and Government organisations globally.  He lives in Massachusetts and is a citizen of the United States of America.

Jaime previously served as the Chief Executive Officer, President and Director of Gomez Inc. a company specialising in monitoring and managing Web site data and Web application performance.  During his tenure he led Gomez Inc. through an IPO registration that resulted in the successful sale of the company for $295M to Compuware Corporation (NASDAQ: CPWR).  He served as Chief Executive Officer, President and Director of S1 Corporation Inc. (NASDAQ: SONE), a software provider to the financial services marketplace. Jaime also orchestrated the highly successful turnaround of Interleaf, Inc. (NASDAQ: LEAF), a provider of software tools for e-content management, culminating in its acquisition for $852M by BroadVision Inc in 2000.  Earlier in his career, Jaime founded several high growth software companies including Openware Technologies Inc., Document Automation Corporation and Purview Technologies Inc..  He has also served on the boards of a number of public and private US and UK based companies including those indicated below.

David Norwood was appointed Chairman of Retroscreen Virology Limited in February 2011 and became Chairman of the Company in April 2012.  David remains as a Non-Executive Director of the Company, with a focus on the Company's business growth and investor strategy.

Kym Denny, Chief Executive Officer, commented, "Retroscreen is expanding the application of its hVIVO platform to address key bottlenecks in the pharmaceutical industry.  I would like to welcome Jaime Ellertson as our new Chairman, with his invaluable experience of developing companies with novel ground breaking technologies into world leaders.  I would like to thank Dave for guiding Retroscreen through its dramatic growth journey and I am delighted that he will continue to serve on the Board.  I am excited to work with our newly shaped Board to deliver our broader vision on a truly global scale."

Mr Ellertson is a director/ partner or has been a director/ partner of the following companies/ partnerships during the previous five years:

Current
Calliope Corporation
Everbridge Europe Ltd.
Everbridge Inc.
Imodus Ltd.
MicroTech Ltd.
Peoplefluent Inc.
PJE Vero LLC.
Qvidian Corporation (previously Kadient Inc.)
Vocal Continuity Solutions Ltd.
Vocal Ltd.
Vocal Mobile Solutions Ltd.

Previous
Cloudfloor Corporation (acquired by Everbridge March 2011)
Danka Business Systems PLC
Gomez Europe Ltd.
Gomez Inc.
Yankee Group Research Inc.

Mr Ellertson does not hold any ordinary shares in the Company.

Save for the information disclosed above there is no other information to be disclosed on Mr Ellertson under Schedule 2(g) of the AIM Rules.

For further information please contact: 
Retroscreen Virology Group plc                                                         +44 207 756 1300
Kym Denny (CEO)
Graham Yeatman (FD) 
Numis Securities Limited                                                                   +44 207 260 1000 
Michael Meade / Freddie Barnfield (Nominated Adviser)
James Black / Michael Burke (Corporate Broking)

Notes to Editors:

Retroscreen Virology Group plc ("Retroscreen") is a rapidly growing UK life sciences company pioneering a technology platform called hVIVO which uses human models of disease involving healthy volunteers to study new drugs and investigate disease in a safe, controlled environment.

Retroscreen has established itself as the world leader in this field through the provision of clinical services to third party study sponsors.  To date, the Company has conducted over 35 clinical studies, involving more than 1600 volunteers for a range of leading industry, governmental and academic clients.

However, Retroscreen's hVIVO platform has a much wider application in helping to understand illness better because the Company believes that the best way to understand human disease is by studying it in humans, not laboratory models.